Screening and identification of significant genes related to tumor metastasis and PSMA in prostate cancer using microarray analysis

Oncology Reports

Volumn 30, Issue 4, 2013, Pages 1920-1928

  Xu, Lin ^a,b   Wang, Zhu ^a,b   Li, Xiao Fei ^b   He, Xia ^a,b   Guan, Lin Lin ^a,b   Tuo, Jiu Ling ^a,b   Wang, Yang ^a,b   Luo, Yanfen ^a,b   Zhong, Hui Ling ^a,b   Qiu, Shao Peng ^b   Cao, Kai Yuan ^a,b  

^a SUN YAT SEN UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

Microarray analysis; Prostate cancer; Prostate specific membrane antigen; Tumor metastasis

Indexed keywords

CADHERIN; COLLAGENASE 3; GELATINASE A; INTERLEUKIN 18; MATRIX METALLOPROTEINASE 16; MONOCYTE CHEMOTACTIC PROTEIN 3; PROSTATE SPECIFIC MEMBRANE ANTIGEN; PROTEIN MDM2; SMALL INTERFERING RNA; SOMATOMEDIN C; STROMAL CELL DERIVED FACTOR 1;

ARTICLE; CCL7 GENE; CDH6 GENE; CELL STRAIN LNCAP; CONTROLLED STUDY; CXCL12 GENE; GENE; GENE EXPRESSION REGULATION; GENE IDENTIFICATION; GENE SILENCING; GENETIC SCREENING; HUMAN; HUMAN CELL; HUMAN TISSUE; IGF1 GENE; IL18 GENE; IL8RB GENE; ITGA7 GENE; ITGB3 GENE; MALE; MDM2 GENE; METASTASIS; MICROARRAY ANALYSIS; MMP13 GENE; MMP2 GENE; MMP3 GENE; MTSS1 GENE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PSMA GENE; REAL TIME POLYMERASE CHAIN REACTION; TSHR GENE;

ANTIGENS, SURFACE; CELL LINE, TUMOR; CELL MOVEMENT; DOWN-REGULATION; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; MALE; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROSTATIC NEOPLASMS; RNA INTERFERENCE; RNA, SMALL INTERFERING; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 84882574569     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2656     Document Type: Article

References (34)

1. Chang SS: Overview of prostate-specific membrane antigen. Rev Urol 6 (Suppl 10): S13-S18, 2004.
2. Kypta R, Unda M and Carracedo A: Is the bench getting closer to the bedside in the war on cancer? A quick look at prostate cancer. Front Endocrinol 3: 53, 2012.
3. Nelson WG, De Marzo AM and Isaacs WB: Prostate cancer. N Engl J Med 349: 366-381, 2003.
4. Paller CJ, Carducci MA and Philips GK: Management of bone metastases in refractory prostate cancer - role of denosumab. Clin Interv Aging 7: 363-372, 2012.
5. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, Feuer EJ and Thun MJ: Cancer statistics. CA Cancer J Clin 54: 8-29, 2004.
6. Germain A, Richardson R, Moul DE, Mammen O, Haas G, Forman SD, Rode N, Begley A and Nofzinger EA: Placebo-controlled comparison of prazosin and cognitive-behavioral treatments for sleep disturbances in US Military Veterans. J Psychosom Res 72: 89-96, 2012.
7. Schroder FH: Progress in understanding androgen-independent prostate cancer (AIPC): a review of potential endocrine-mediated mechanisms. Eur Urol 53: 1129-1137, 2008.
8. Kasper S and Cookson MS: Mechanisms leading to the development of hormone-resistant prostate cancer. Urol Clin North Am 33: 201-210, vii, 2006.
9. Pinto JT, Suffoletto BP, Berzin TM, Qiao CH, Lin S, Tong WP, May F, Mukherjee B and Heston WD: Prostate-specific membrane antigen: a novel folate hydrolase in human prostatic carcinoma cells. Clin Cancer Res 2: 1445-1451, 1996.
10. Robinson MB, Blakely RD, Couto R and Coyle JT: Hydrolysis of the brain dipeptide N-acetyl-L-aspartyl-L-glutamate. Identification and characterization of a novel N-acetylated alpha-linked acidic dipeptidase activity from rat brain. J Biol Chem 262: 14498-14506, 1987.
11. Cao KY, Mao XP, Wang DH, Xu L, Yuan GQ, Dai SQ, Zheng BJ and Qiu SP: High expression of PSM-E correlated with tumor grade in prostate cancer: a new alternatively spliced variant of prostate-specific membrane antigen. Prostate 67: 1791-1800, 2007.
12. Cao KY, Xu L, Zhang DM, Zhang XM, Zhang T, He X, Wang Z, Feng FS, Qiu SP and Shen GX: New alternatively spliced variant of prostate-specific membrane antigen PSM-E suppresses the proliferation, migration and invasiveness of prostate cancer cells. Int J Oncol 40: 1977-1985, 2012.
13. Ghosh A and Heston WD: Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J Cell Biochem 91: 528-539, 2004.
14. Frigerio B, Fracasso G, Luison E, Cingarlini S, Mortarino M, Coliva A, Seregni E, Bombardieri E, Zuccolotto G, Rosato A, Colombatti M, Canevari S and Figini M: A single-chain fragment against prostate specific membrane antigen as a tool to build theranostic reagents for prostate cancer. Eur J Cancer, pii: S0959-8049(13)00087-7. doi: 10.1016/j.ejca.2013.01.024., 2013.
15. Zhao LY, Mao XP, Chao KY, Guo SJ and Qiu SP: Prostate-specific membrane antigen can promote in vivo osseous metastasis of prostate cancer cells in mice. Braz J Med Biol Res 45: 737-745, 2012.
16. Mannweiler S, Amersdorfer P, Trajanoski S, Terrett JA, King D and Mehes G: Heterogeneity of prostate-specific membrane antigen (PSMA) expression in prostate carcinoma with distant metastasis. Pathol Oncol Res 15: 167-172, 2009.
17. Ghosh A, Wang X, Klein E and Heston WD: Novel role of prostate-specific membrane antigen in suppressing prostate cancer invasiveness. Cancer Res 65: 727-731, 2005.
18. Xie BX, Zhang H, Wang J, Pang B, Wu RQ, Qian XL, Yu L, Li SH, Shi QG, Huang CF and Zhou JG: Analysis of differentially expressed genes in LNCaP prostate cancer progression model. J Androl 32: 170-182, 2010.
19. Wang G, Firoz EF, Rose A, Blochin E, Christos P, Pollens D, Mazumdar M, Gerald W, Oddoux C, Lee P and Osman I: MDM2 expression and regulation in prostate cancer racial disparity. Int J Clin Exp Pathol 2: 353-360, 2009.
20. Kohn EC: Invasion and metastasis: biology and clinical potential. Pharmacol Ther 52: 235-244, 1991.
21. Duffy MJ, McGowan PM and Gallagher WM: Cancer invasion and metastasis: changing views. J Pathol 214: 283-293, 2008.
22. Kong L, Yuan Q, Zhu H, Li Y, Guo Q, Wang Q, Bi X and Gao X: The suppression of prostate LNCaP cancer cells growth by Selenium nanoparticles through Akt/Mdm2/AR controlled apoptosis. Biomaterials 32: 6515-6522, 2011.
23. Roomi MW, Monterrey JC, Kalinovsky T, Rath M and Niedzwiecki A: Inhibition of invasion and MMPs by a nutrient mixture in human cancer cell lines: a correlation study. Exp Oncol 32: 243-248, 2011.
24. Loberg RD, Neeley CK, Adam-Day LL, Fridman Y, St John LN, Nixdorf S, Jackson P, Kalikin LM and Pienta KJ: Differential expression analysis of MIM (MTSS1) splice variants and a functional role of MIM in prostate cancer cell biology. Int J Oncol 26: 1699-1705, 2005.
25. Inoue T, Inoue YU, Asami J, Izumi H, Nakamura S and Krumlauf R: Analysis of mouse Cdh6 gene regulation by transgenesis of modified bacterial artificial chromosomes. Dev Biol 315: 506-520, 2008.
26. Mendes O, Kim HT and Stoica G: Expression of MMP2, MMP9 and MMP3 in breast cancer brain metastasis in a rat model. Clin Exp Metastasis 22: 237-246, 2005.
27. Chang HJ, Yang MJ, Yang YH, Hou MF, Hsueh EJ and Lin SR: MMP13 is potentially a new tumor marker for breast cancer diagnosis. Oncol Rep 22: 1119-1127, 2009.
28. Wang W, Wu W, Desai T, Ward DC and Kaufman SJ: Localization of the alpha 7 integrin gene (ITGA7) on human chromosome 12q13: clustering of integrin and Hox genes implies parallel evolution of these gene families. Genomics 26: 568-570, 1995.
29. Samson T, Smyth N, Janetzky S, Wendler O, Müller JM, Schüle R, von der Mark H, von der Mark K and Wixler V: The LIM-only proteins FHL2 and FHL3 interact with α- and β-subunits of the muscle α7β1 integrin receptor. J Biol Chem 279: 28641-28652, 2004.
30. Zhu ZH, Yu YP, Zheng ZL, Song Y, Xiang GS, Nelson J, Michalopoulos G and Luo JH: Integrin alpha 7 interacts with high temperature requirement A2 (HtrA2) to induce prostate cancer cell death. Am J Pathol 177: 1176-1186, 2010.
31. Mazzoccoli G, Sothern RB, Pazienza V, Piepoli A, Muscarella LA, Giuliani F and Tarquini R: Circadian aspects of growth hormone-insulin-like growth factor axis function in patients with lung cancer. Clin Lung Cancer 13: 68-74, 2011.
32. Montagnani Marelli M, Moretti RM, Procacci P, Motta M and Limonta P: Insulin-like growth factor-I promotes migration in human androgen-independent prostate cancer cells via the αvβ3 integrin and PI3-K/Akt signaling. Int J Oncol 28: 723-730, 2006.
33. Nickerson T, Chang F, Lorimer D, Smeekens SP, Sawyers CL and Pollak M: In vivo progression of LAPC-9 and LNCaP prostate cancer models to androgen independence is associated with increased expression of insulin-like growth factor I (IGF-I) and IGF-I receptor (IGF-IR). Cancer Res 61: 6276-6280, 2001.
34. Uygur B and Wu WS: SLUG promotes prostate cancer cell migration and invasion via CXCR4/CXCL12 axis. Mol Cancer 10: 139, 2011.